India’s DNA COVID vaccine is a world first – more are coming

India has approved a new COVID-19 vaccine that uses circular strands of DNA to prime the immune system against the virus SARS-CoV-2. Researchers have welcomed news of the first DNA vaccine for people to receive approval anywhere in the world, and say many other DNA vaccines might soon be hot on its heels.

ZyCoV-D, which is administered into the skin without an injection, has been found to be 67% protective against symptomatic COVID-19 in clinical trials, and will probably start to be administered in India this month. Although the efficacy is not particularly high compared to that of many other COVID-19 vaccines, the fact that it is a DNA vaccine is significant, say researchers.

It is proof of the principle that DNA vaccines work and can help in controlling the pandemic, says Peter Richmond, a paediatric immunologist at the University of Western Australia in Perth. “This is a really important step forward in the fight to defeat COVID-19 globally, because it demonstrates that we have another class of vaccines that we can use.”

Close to a dozen DNA vaccines against COVID-19 are in clinical trials globally, and at least as many again are in earlier stages of development. DNA vaccines are also being developed for many other diseases.

“If DNA vaccines prove to be successful, this is really the future of vaccinology” because they are easy to manufacture, says Shahid Jameel, a virologist at Ashoka University in Sonipat, India.

Fast-tracked development

The urgency of combating COVID-19 has fast-tracked the development of vaccines that use genetic technology, such as messenger RNA and DNA vaccines, says David Weiner, director of the Vaccine & Immunotherapy Center at the Wistar Institute in Philadelphia, Pennsylvania.

RNA vaccines were quicker to show strong immune responses in clinical trials; they have now been delivered to hundreds of millions of people around the world. But DNA vaccines have a number of benefits, because they are easy to produce and the finished products are more stable than mRNA vaccines, which typically require storage at very low temperatures.

ZyCoV-D was developed by Indian pharmaceutical firm Zydus Cadila, headquartered in Ahmedabad. On 20 August, India’s drug regulator authorized the vaccine for people aged 12 and older. The efficacy figure of 67% came from trials involving more than 28,000 participants, which saw 21 symptomatic cases of COVID-19 in the vaccinated group and 60 among people who received a placebo.

ZyCoV-D contains circular strands of DNA known as plasmids, which encode the spike protein of SARS-CoV-2, together with a promoter sequence for turning the gene on. Once the plasmids enter the nuclei of cells, they are converted into mRNA, which travels to the main body of the cell, the cytoplasm, and is translated into the spike protein itself. The body’s immune system then mounts a response against the protein, and produces tailored immune cells that can clear future infections. Plasmids typically degrade within weeks to months, but the immunity remains.

Both DNA and mRNA vaccines have been under development since the 1990s, says Weiner. The challenge for DNA vaccines is that they need to make it all the way to the cell nucleus, unlike mRNA vaccines, which just need to get to the cytoplasm, says Jameel. So, for a long time, DNA vaccines struggled to induce potent immune responses in clinical trials, which is why they had been approved for use as vaccines only in animals, such as horses, until now.

Nature 597, 161-162 (2021)

doi: https://doi.org/10.1038/d41586-021-02385-x

Related Articles

• How COVID unlocked the power of RNA vaccines

• Malaria vaccine shows promise — now come tougher trials

• COVID research: a year of scientific milestones

Subjects

• Infection
• Technology
• Vaccines
• Biotechnology
• Genetics

Latest on:

Infection

Why a teenager’s bird-flu infection is ringing alarm bells for scientists

News Explainer 20 NOV 24

Health of people who are displaced in their own countries is a neglected global crisis

Comment 19 NOV 24

Animal-to-human viral leap sparked deadly Marburg outbreak

News 24 OCT 24

Technology

Why tumour geography matters — and how to map it

Technology Feature 25 NOV 24

Notching up a win: fresh tools for activating Notch

Technology Feature 21 NOV 24

AI could pose pandemic-scale biosecurity risks. Here’s how to make it safer

Comment 21 NOV 24

Vaccines

This malaria vaccine is delivered by a mosquito bite

News 20 NOV 24

Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1

Article 07 NOV 24

Mumps is rising in some nations — but a fresh dose of vaccine might help

Research Highlight 14 OCT 24